1. Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study
- Author
-
Laura Martinez Valenzuela, Marian Goicoechea, Clara Maria Cases Corona, Javier Carbayo, Ana Huerta, Natalia Ramos Terrada, Tamara Gelen Malek-Marín, Amir Shabaka, Anna Pocurull, Ana Pérez de José, Loreto Fernandez Lorente, Teresa Bada-Bosch, Institut Català de la Salut, [Pérez de José A, Carbayo J] Department of Nephrology, University Hospital Gregorio Marañón, Madrid, Spain. [Pocurull A] Department of Gastroenterology and Hepatology, Hospital Clínic de Barcelona, Barcelona, Spain. [Bada-Bosch T] Department of Nephrology, Hospital Universitario Doce de Octubre, Madrid, Spain. [Cases Corona CM] Department of Nephrology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain. [Shabaka A] Department of Nephrology, Hospital Clínico Universitario San Carlos, Madrid, Spain. [Ramos Terrada N] Servei de Nefrologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
hepatitis C virus ,medicine.medical_specialty ,direct-acting antiviral agents ,membranoproliferative glomerulonephritis ,Hepatitis C virus ,cryoglobulinaemia ,Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, Chronic [DISEASES] ,medicine.disease_cause ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Interquartile range ,Internal medicine ,Medicine ,Other subheadings::/therapeutic use [Other subheadings] ,AcademicSubjects/MED00340 ,Medicaments antivírics - Ús terapèutic - Eficàcia ,030304 developmental biology ,virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica [ENFERMEDADES] ,0303 health sciences ,Transplantation ,Kidney diseases ,Otros calificadores::/uso terapéutico [Otros calificadores] ,business.industry ,Surrogate endpoint ,Ribavirin ,Hazard ratio ,diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Original Articles ,Hepatitis C ,Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,medicine.disease ,Cryoglobulinemia ,Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS] ,chemistry ,Nephrology ,acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS] ,Virus de l'hepatitis C ,Malalties del ronyó ,030211 gastroenterology & hepatology ,business ,Cohort study - Abstract
Background Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated mixed cryoglobulinaemia (HCV-MC) has been little studied. The aim of this study was to analyse the effects of antiviral treatment on kidney prognosis and evolution in patients diagnosed with HCV-MC. Methods The RENALCRYOGLOBULINEMIC study is an observational multicentre cohort study of 139 patients with HCV-MC from 14 Spanish centres. Clinical and laboratory parameters were measured before and after antiviral treatment. Primary endpoints were kidney survival and mortality after HCV-MC diagnosis. Secondary endpoints were clinical, immunological and virological responses after antiviral treatment. Results Patients were divided into three groups based on the treatment received: treatment with DAAs (n = 100) treatment with interferon (IFN) and ribavirin (RBV) (n = 24) and no treatment (n = 15). Patients were followed up for a median duration of 138 months (interquartile range 70–251. DAA treatment reduced overall mortality {hazard ratio [HR] 0.12 [95% confidence interval (CI) 0.04–0.40]; P Conclusions Results from the RENALCRYOGLOBULINEMIC study indicated that DAA treatment in patients with HCV-MC improves kidney survival and reduces mortality.
- Published
- 2020